Sonnet BioTherapeutics (SONN) Competitors $4.30 -0.02 (-0.46%) (As of 12:38 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SONN vs. TSBX, KPRX, VINC, ADXN, EDSA, INDP, PHXM, RDHL, CDT, and RNAZShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Turnstone Biologics (TSBX), Kiora Pharmaceuticals (KPRX), Vincerx Pharma (VINC), Addex Therapeutics (ADXN), Edesa Biotech (EDSA), Indaptus Therapeutics (INDP), PHAXIAM Therapeutics (PHXM), RedHill Biopharma (RDHL), Conduit Pharmaceuticals (CDT), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Turnstone Biologics Kiora Pharmaceuticals Vincerx Pharma Addex Therapeutics Edesa Biotech Indaptus Therapeutics PHAXIAM Therapeutics RedHill Biopharma Conduit Pharmaceuticals TransCode Therapeutics Turnstone Biologics (NASDAQ:TSBX) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Which has higher valuation and earnings, TSBX or SONN? Sonnet BioTherapeutics has lower revenue, but higher earnings than Turnstone Biologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTurnstone Biologics$19.31M0.57-$55.20M-$3.50-0.14Sonnet BioTherapeutics$150K19.49-$18.83MN/AN/A Does the MarketBeat Community prefer TSBX or SONN? Sonnet BioTherapeutics received 15 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 82.61% of users gave Sonnet BioTherapeutics an outperform vote while only 57.14% of users gave Turnstone Biologics an outperform vote. CompanyUnderperformOutperformTurnstone BiologicsOutperform Votes457.14% Underperform Votes342.86% Sonnet BioTherapeuticsOutperform Votes1982.61% Underperform Votes417.39% Do analysts prefer TSBX or SONN? Turnstone Biologics currently has a consensus target price of $2.13, indicating a potential upside of 348.41%. Sonnet BioTherapeutics has a consensus target price of $30.00, indicating a potential upside of 599.30%. Given Sonnet BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sonnet BioTherapeutics is more favorable than Turnstone Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turnstone Biologics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor TSBX or SONN? In the previous week, Turnstone Biologics' average media sentiment score of 0.00 equaled Sonnet BioTherapeutics'average media sentiment score. Company Overall Sentiment Turnstone Biologics Neutral Sonnet BioTherapeutics Neutral Which has more risk and volatility, TSBX or SONN? Turnstone Biologics has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Is TSBX or SONN more profitable? Turnstone Biologics' return on equity of -85.18% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Turnstone BiologicsN/A -85.18% -72.25% Sonnet BioTherapeutics N/A -398.45%-142.16% Do institutionals & insiders hold more shares of TSBX or SONN? 52.5% of Turnstone Biologics shares are held by institutional investors. Comparatively, 9.5% of Sonnet BioTherapeutics shares are held by institutional investors. 32.1% of Turnstone Biologics shares are held by company insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummarySonnet BioTherapeutics beats Turnstone Biologics on 7 of the 13 factors compared between the two stocks. Ad Weiss RatingsThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”Click here to find out more about what could be Trump and JD Vance’s favorite coin. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.92M$6.75B$5.02B$8.42BDividend YieldN/A7.94%7.49%4.16%P/E RatioN/A11.78128.4816.64Price / Sales19.49288.471,723.1677.30Price / CashN/A46.0936.9033.53Price / Book-4.175.284.595.19Net Income-$18.83M$150.82M$113.94M$223.67M7 Day Performance-13.48%-0.69%110.64%2.76%1 Month Performance-16.50%15.56%124.65%8.82%1 Year Performance233.33%37.06%155.07%29.33% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics1.4172 of 5 stars$4.30-0.5%$30.00+597.7%+234.9%$2.92M$150,000.000.0012Gap DownTSBXTurnstone Biologics3.6084 of 5 stars$0.50-5.6%$2.13+324.0%-84.5%$11.59M$19.31M-0.1482Positive NewsKPRXKiora Pharmaceuticals3.7844 of 5 stars$3.85-4.7%$10.00+159.7%-35.5%$11.23M$16M0.0010Gap UpHigh Trading VolumeVINCVincerx Pharma2.4421 of 5 stars$0.37flat$2.00+440.5%-62.4%$11.05MN/A-0.2860ADXNAddex Therapeutics1.4788 of 5 stars$10.41-5.4%$30.00+188.2%+76.8%$11.04M$829,941.00-6.3530Upcoming EarningsEDSAEdesa Biotech2.9622 of 5 stars$3.33-2.1%$21.00+530.6%-9.6%$10.81MN/A0.0020INDPIndaptus Therapeutics3.835 of 5 stars$1.24-19.5%$12.00+867.7%-53.4%$10.59MN/A-0.676Positive NewsGap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049News CoverageRDHLRedHill Biopharma0.8446 of 5 stars$8.01-2.4%N/A-96.5%$10.17M$6.53M0.00210CDTConduit PharmaceuticalsN/A$0.10flatN/A-93.0%$10.06MN/A0.003Gap DownRNAZTransCode Therapeutics2.2522 of 5 stars$0.56-6.7%$3.00+435.4%-96.6%$9.68MN/A0.009Gap Up Related Companies and Tools Related Companies Turnstone Biologics Competitors Kiora Pharmaceuticals Competitors Vincerx Pharma Competitors Addex Therapeutics Competitors Edesa Biotech Competitors Indaptus Therapeutics Competitors PHAXIAM Therapeutics Competitors RedHill Biopharma Competitors Conduit Pharmaceuticals Competitors TransCode Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SONN) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
